Ra’anana-based Inspira Technologies today announced the signing of a non-binding Letter of Intent with Shamir Medical Center (Assaf Harofeh), a step the company hopes will lead to providing better respiratory care both here in Israel and in the global community.
“With the anticipated FDA approval on the horizon, I am confident that this prospective collaboration with Shamir Medical Center will enhance the efficacy of life-support care and establish a pathway for its adoption in both local and international markets,” president of Inspira Technologies Joe Hayo said in a press release.
The Letter of Intent (LOI) with Shamir will test the performance of the INSPIRA ART100, an innovative blood oxygenation technology that directly oxygenates blood and immediately elevates and stabilizes patient oxygen levels, in a real-world clinical environment. The LOI hinges on the approval by the Israeli Ministry of Health.
Keep reading at nocamels.com.
Inspira Technologies CTO Daniella Yeheskely-Hayon is a Technion alumna.
More Health & Medicine stories
New System Eases Patient Discharge Process
